Ibrutinib Production Cost Reports

The report provides a detailed analysis essential for establishing an Ibrutinib production plant. It encompasses all critical aspects necessary for Ibrutinib production, including the cost of Ibrutinib production, Ibrutinib plant cost, Ibrutinib production costs, and the overall Ibrutinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Ibrutinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Ibrutinib (brand name Imbruvica) is a targeted oral drug utilised in the pharmaceutical industry as a targeted therapy for the treatment of various B-cell malignancies, such as chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD). Its mechanism of action is as a Bruton's tyrosine kinase (BTK) inhibitor, which disrupts cancer cell signalling pathways. The drug's intermediates are synthesised for use in active pharmaceutical ingredient (API) production to support these therapies. Advanced techniques like hot-melt extrusion are employed to create sustained-release formulations, enhancing the drug's delivery and efficacy.

The market demand for Ibrutinib is driven by the rising global prevalence of B-cell malignancies such as chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL), coupled with an ageing population that increases demand for targeted therapies. Regulatory approvals for expanded indications, ongoing clinical trials for combination therapies, and label extensions further propel adoption, while research addressing resistance mechanisms enhances its efficacy profile.

Additional factors include improved patient access in emerging markets like the Asia Pacific through rising healthcare expenditures and government initiatives, as well as the shift toward personalised medicine and real-world evidence supporting long-term safety. Furthermore, regulatory compliance, including FDA approvals for formulations like 140mg, 280mg, and 420mg tablets, along with patent protections extended by orphan drug designations and Paragraph IV settlements delaying generics until 2032, impacts industrial Ibrutinib procurement.

Raw Material for Ibrutinib Production

According to the Ibrutinib production plant project report, the various raw materials for Ibrutinib production include pyrazolo[3,4-d]pyrimidine core compound and tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate.

Production Process of Ibrutinib

The extensive Ibrutinib production cost report consists of the following major industrial production process:

1. Production via a multi-step chemical synthesis: The production process of Ibrutinib occurs through a multi-step chemical process starting with a pyrazolo[3,4-d]pyrimidine core, which undergoes a Mitsunobu reaction with tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate to introduce the piperidine moiety, followed by acidic deprotection to yield the free amine intermediate. In the next step, 4-phenoxyphenyl substituent is installed via Suzuki coupling. The final step involves acylation of the piperidine nitrogen using acryloyl chloride in the presence of a base in a biphasic system to produce high-purity ibrutinib.

Properties of Ibrutinib

Ibrutinib is a small molecule BTK inhibitor with the molecular formula C25H24N6O2 and a molecular weight of about 440.5 g/mol. It is obtained as a white to off white solid with very low solubility in water at neutral pH but higher solubility in strongly acidic conditions, which is important for oral delivery. It features an aminopyrazolopyrimidine core, a piperidinyl group, and an electrophilic acrylamide side chain that enables covalent binding to a cysteine residue in BTK. It behaves as a weakly basic, moderately lipophilic compound often categorised as a poorly soluble, highly permeable (BCS class II like) drug. Additionally, solid state studies show distinct crystalline melting behaviour, while amorphous forms and engineered cocrystals are explored to enhance its solubility and thermal stability for formulation purposes.